APR TD011
Epidermolysis Bullosa
Clinical DevelopmentActive
Key Facts
Indication
Epidermolysis Bullosa
Phase
Clinical Development
Status
Active
Company
About APR Applied Pharma Research
APR Applied Pharma Research is a mission-driven Swiss pharma company focused on improving the lives of patients with rare diseases through innovative, patent-protected products. The company has successfully built a portfolio of marketed products, including PKU GOLIKE® and Nexodyn®, and maintains a promising clinical pipeline. Its strategy integrates direct commercialization in key European markets with a global partner network and a complementary CDMO services division, creating a diversified and resilient business.
View full company profileTherapeutic Areas
Other Epidermolysis Bullosa Drugs
| Drug | Company | Phase |
|---|---|---|
| TXA127 (Potential) | Constant Therapeutics | Pre-clinical or Undisclosed |
| Mas/MrgD Agonist Program | Xitra Therapeutics | Pre-clinical |